A Sub-Study to Explore Association Patterns Between Digital Outcome Assessments From the Konectomâ„¢ Platform and Magnetic Resonance Imaging (MRI) Measures of Brain Tissue Damage

Sponsor
Biogen (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05106465
Collaborator
(none)
500
1
11.9
42

Study Details

Study Description

Brief Summary

The purpose of the study is to explore association patterns between digital outcome assessments from Konectom and MRI measures of brain tissue damage.

Condition or Disease Intervention/Treatment Phase
  • Device: Konectom platform

Study Design

Study Type:
Observational
Anticipated Enrollment :
500 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Konect-MS: A Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) Sub-Study to Explore Association Patterns Between Digital Outcome Assessments From the Konectomâ„¢ Platform and MRI Measures of Brain Tissue Damage
Actual Study Start Date :
Dec 15, 2021
Anticipated Primary Completion Date :
Dec 12, 2022
Anticipated Study Completion Date :
Dec 12, 2022

Arms and Interventions

Arm Intervention/Treatment
Konectom

Participants with a diagnosis of MS or clinically isolated syndrome who are enrolled in Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) and who own a smartphone model compatible with the Konectom platform will be enrolled.

Device: Konectom platform
Administered as specified in the treatment arm.

Outcome Measures

Primary Outcome Measures

  1. Correlation Between Konectom Tests and MRI Measures of Brain Tissue Damage [Up to 1 year]

    Konectom tests include cognitive processing speed test (CPST), pinching test, drawing test, static balance test (SBT)/u-turn test (UTT) and 6-minute walking test (6MWT).

Secondary Outcome Measures

  1. Correlation Between Konectom Tests and Deep Radiomic Feature Set Extracted From Fluid-attenuated Inversion Recovery (FLAIR) Hyperintense MS Lesions Using 3D-T1 and 3D FLAIR Data [Up to 1 year]

    Konectom tests include CPST, pinching test, drawing test, SBT/UTT and 6MWT.

  2. Correlation Between Konectom Tests and Deep Radiomic Feature Set Extracted From the Normal Appearing White Matter Using 3D-T1 and 3D FLAIR Data [Up to 1 year]

    Konectom tests include CPST, pinching test, drawing test, SBT/UTT and 6MWT.

  3. Correlation Between Konectom Tests and Deep Radiomic Feature Set Extracted From the Cortex Using 3D-T1 and 3D FLAIR Data [Up to 1 year]

    Konectom tests include CPST, pinching test, drawing test, SBT/UTT and 6MWT.

  4. Correlation Between Konectom Tests and Deep Radiomic Feature Set Extracted From Deep Grey Matter Using 3D-T1 and 3D FLAIR Data [Up to 1 year]

    Konectom tests include CPST, pinching test, drawing test, SBT/UTT and 6MWT.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Should be enrolled in multiple sclerosis partners advancing technology and health solutions (MS PATHS).

  • Participant (or participant's legal representative) has the ability to understand the purpose and risks of the study, to provide signed and dated informed consent, and to authorize the use of confidential health information in accordance with national and local privacy regulations.

  • Should have literacy of written language in which the software and Instructions for use are displayed (User Interface [UI], Instructions).

Exclusion Criteria:
  • Unable or unwilling to provide informed consent.

  • Inability to use a smartphone as per physician's opinion.

  • Not owning a Konectom-compatible smartphone.

  • Other unspecified reasons that, in the opinion of the Investigator or Biogen, make the participant unsuitable for participation in the sub-study. A participant only needs to complete the assessments deemed necessary by the Investigator.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Research Site Dresden Germany 01307

Sponsors and Collaborators

  • Biogen

Investigators

  • Study Director: Medical Director, Biogen

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Biogen
ClinicalTrials.gov Identifier:
NCT05106465
Other Study ID Numbers:
  • 888MS008
First Posted:
Nov 3, 2021
Last Update Posted:
Jan 20, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 20, 2022